AdaptHealth Corp. (NASDAQ:AHCO) Receives $27.17 Consensus Price Target from Analysts

Shares of AdaptHealth Corp. (NASDAQ:AHCOGet Rating) have been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $27.17.

AHCO has been the subject of several recent research reports. TheStreet raised shares of AdaptHealth from a “d+” rating to a “c-” rating in a research note on Tuesday, August 2nd. SVB Leerink increased their target price on shares of AdaptHealth from $24.00 to $29.00 and gave the company an “outperform” rating in a research note on Wednesday, August 10th. Deutsche Bank Aktiengesellschaft increased their target price on shares of AdaptHealth from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Truist Financial upped their price target on shares of AdaptHealth from $26.00 to $28.00 and gave the company a “buy” rating in a research report on Monday.

Insider Activity at AdaptHealth

In related news, General Counsel Christopher J. Joyce sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $22.20, for a total value of $2,220,000.00. Following the completion of the sale, the general counsel now owns 106,071 shares in the company, valued at approximately $2,354,776.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other AdaptHealth news, major shareholder Everest Hill Group Inc. sold 159,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $23.00, for a total value of $3,657,000.00. Following the transaction, the insider now owns 15,485,834 shares in the company, valued at approximately $356,174,182. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel Christopher J. Joyce sold 100,000 shares of the stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $22.20, for a total transaction of $2,220,000.00. Following the transaction, the general counsel now owns 106,071 shares in the company, valued at approximately $2,354,776.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 474,382 shares of company stock worth $10,938,477. 17.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Rhumbline Advisers increased its stake in shares of AdaptHealth by 0.6% during the 4th quarter. Rhumbline Advisers now owns 101,502 shares of the company’s stock worth $2,483,000 after purchasing an additional 593 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of AdaptHealth by 96.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,710 shares of the company’s stock worth $27,000 after purchasing an additional 840 shares during the last quarter. First Republic Investment Management Inc. increased its stake in shares of AdaptHealth by 3.8% during the 2nd quarter. First Republic Investment Management Inc. now owns 24,990 shares of the company’s stock worth $451,000 after purchasing an additional 924 shares during the last quarter. Teacher Retirement System of Texas increased its stake in shares of AdaptHealth by 6.1% during the 1st quarter. Teacher Retirement System of Texas now owns 16,197 shares of the company’s stock worth $260,000 after purchasing an additional 927 shares during the last quarter. Finally, Covestor Ltd acquired a new position in shares of AdaptHealth during the 4th quarter worth $35,000. Institutional investors and hedge funds own 75.76% of the company’s stock.

AdaptHealth Trading Down 1.9 %

Shares of NASDAQ:AHCO opened at $19.99 on Tuesday. The company has a 50 day moving average of $20.93 and a 200-day moving average of $18.12. The firm has a market cap of $2.68 billion, a P/E ratio of 38.44, a P/E/G ratio of 0.36 and a beta of 0.59. AdaptHealth has a twelve month low of $11.40 and a twelve month high of $28.75. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 1.02.

AdaptHealth (NASDAQ:AHCOGet Rating) last released its earnings results on Tuesday, August 9th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.23). AdaptHealth had a net margin of 4.91% and a return on equity of 6.49%. The business had revenue of $727.61 million for the quarter, compared to analyst estimates of $724.27 million. During the same period in the prior year, the company earned ($0.11) earnings per share. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. As a group, analysts anticipate that AdaptHealth will post 1.32 earnings per share for the current fiscal year.

AdaptHealth Company Profile

(Get Rating)

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

Read More

Analyst Recommendations for AdaptHealth (NASDAQ:AHCO)

Receive News & Ratings for AdaptHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdaptHealth and related companies with MarketBeat.com's FREE daily email newsletter.